Evidence map›Paper›PMID 40486290›Full record

ArticleAdvances in radiation oncology2025

I Frank Ciernik, Shubeen Singh, Akash K Singh, Philipp Goldschmidt, Wilfried Budach, Dirk Vordermark, Jérôme Krayenbuehl

Abstract read
In one paragraph

Article in Advances in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

I Frank CiernikMedical School, University of Zürich, Zurich, Switzerland.
Shubeen SinghMedical School, University of Zürich, Zurich, Switzerland.
Akash K SinghDepartment of Radiation Oncology, Städtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany.
Philipp GoldschmidtDepartment of Radiation Oncology, Städtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane, Dessau, Germany.
Wilfried BudachDepartment of Radiation Oncology, University Hospital, Heinrich Heine University, Düsseldorf, Germany.
Dirk VordermarkDepartment of Radiation Oncology, University Hospital, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Germany.
Jérôme KrayenbuehlDepartment of Radiation Oncology, University Hospital, University of Zürich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The maximal dose for partial breast irradiation (PBI) with stereotactic body radiation therapy for definitive local therapy of nonmetastatic breast cancer has not been established. Here we evaluate the maximal achievable coverage of the planning target volume suitable for PBI without violating organs-at-risk constraints. Methods and Materials: Planning computed tomography scans of 22 patients with pulmonary or cardiac risk factors and left-sided disease in prone and supine position (sp) were obtained. Plans for PBI in 5 fractions were generated according to the Guidelines of the American Society for Radiation Oncology. Maximum tolerated dose (MTD) was defined when the dose reached any constraint of a neighboring organ based on recommendations of the American Association for Physics in Medicine. Results: Mean MTD was 45.9 ± 3.9 Gy (range, 38.8-53.9) in sp and 46.1 ±3.2 Gy (range, 37.3-53.9) in prone position (pp), respectively. The MTD was ≥44.3 Gy in sp and ≥44.8 Gy in pp in 95% of patients. Fat tissue was the dose limiting structure in 11 of 22 patients in sp and 15 of 22 in pp. D Conclusions: For definitive stereotactic body radiation therapy for early-stage breast cancer, we propose a dose escalation starting with 45 Gy in 5 fractions to be tested in a clinical trial. Prone position is advised for tumors close to the thoracic cage.

Identifiers

PMID40486290
PMCPMC12142499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.